IP Library Granted Patent US 9,040,664
Granted Patent B2
US 9,040,664 · App. 10/553,570 · Granted May 26, 2015

Materials and methods for preparing protein-polymer conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,664
App. No.
10/553,570
Granted
May 26, 2015
Kind
B2
Abstract

The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.

Claims (13)

1. A method for preparing a site-specific insulin-PEG conjugate comprising:

(a) contacting insulin protein with PEG in an aqueous solution in the presence of at least one organic solvent selected from the group consisting of ethanol, methanol, DMSO, dioxane, DMF, and NMP and at least one metal chelator selected from the group consisting of metal ion chelators, EDTA, deferoxamine (DEF), diethylenetriamine pentaacetic acid (DTPA), and bis(aminoethyl)glycolether N,N,N′,N′-tetraacetic acid (EGTA), to form the site-specific insulin-PEG conjugate by a predominant reaction of the insulin protein at residue PheB1 without protecting the insulin protein at GlyA1 and LysB29 residues, and

(b) isolating the conjugate.

2. The method of claim 1 , wherein the insulin protein comprises human insulin.

3. The method of claim 1 , wherein the PEG comprises an amino-reactive PEG derivative selected from the group consisting of an aldehyde, a N-hydroxy succinimide, a PNP-carbonate, and a benzotrizole terminated hydrophilic polymer.

4. The method of claim 1 , wherein the PEG and insulin protein are contacted at a molar ratio of about 10:1-1:1.

5. The method of claim 1 , wherein the organic solvent is present at a concentration of about 0.1 to 10%.

6. The method of claim 1 , wherein the insulin protein and the PEG are contacted at a pH of about 5.0-7.5.

7. The method of claim 1 , wherein the metal chelator is present at a concentration of about 0.1-10 mM.

8. The method of claim 1 , wherein the insulin protein and the PEG are contacted at a temperature of about 4-50° C.

9. The method of claim 1 , wherein the method further comprises the step of quenching formation of the conjugate prior to the isolating of the conjugate.

10. The method of claim 1 , further comprising the step of:

(c) encapsulating the isolated conjugate in a biodegradable polymer.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 1, 2022
From: SLR INVESTMENT CORP
To: REZOLUTE, INC.
Reel/Frame 060419/0315 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 15, 2021
From: REZOLUTE, INC.
To: SLR INVESTMENT CORP., AS COLLATERAL AGENT
Reel/Frame 055949/0730 →
MERGER AND CHANGE OF NAME Recorded Mar 1, 2018
From: ANTRIABIO, INC.; REZOLUTE, INC.
To: REZOLUTE, INC.
Reel/Frame 045082/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2013
From: KIMBERLEY H. TYSON - CHAPTER 7 TRUSTEE
To: ANTRIABIO, INC.
Reel/Frame 030687/0456 →